This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BODEN, G. Articles by RUDNICK, M. R. Search for Related Content PubMed PubMed Citation Articles by BODEN, G. Articles by RUDNICK, M. R.

Human Pancreatic Polypeptide in Chronic Renal Failure and Cirrhosis of the Liver: Role of Kidneys and Liver in Pancreatic Polypeptide Metabolism^*

Department of Medicine and the General Clinical Research Center, Temple University Health Sciences Center Philadelphia, Pennsylvania 19140

Address all correspondence and requests for reprints to: Guenther Boden, M.D.,Temple University Hospital, 3401 N. Broad Street, Philadelphia, Pennsylvania 19140.

Basal plasma concentrations of human pancreaticpolypeptide (PP) were measured in 14 patients with chronic renal failure (CRF), 13 patients with cirrhosis of the liver, and age-matched controls. PP was significantly higher in patients with CRF than in controls (817 ± 183 vs. 157 ± 118 pg/ ml; P < 0.005). The degree of PP elevation in patients with CRF correlated well with thedegree of their renal insufficiency (r = 0.85; P < 0.001). Fractionation of plasma over Sephadex G-50 columns revealed comparable elution patterns in patients with CRFand in normal controls. Hemodialysis had no effect on the PP concentration. We also determined arterial venous PP concentration differences and plasma blood flow across thekidneys and liver in 13 patients with cirrhosis and arteriovenous differences across of the liver in 13 controls with normal hepatic and renal functions. The mean PP concentration was significantly higher in arterial plasma than in renal venous plasma (143 ± 24 vs. 123 ± 23 pg/ml; P < 0.025). Renal fractional extraction was 17.2 ± 6.6%, and renal clearance of PP was 151 ± 47 ml/min. No significant extraction of PP occurred across theliver. It is concluded that the kidneys, but not the liver, are important sites for themetabolism of PP and that elevated PP concentrations in patients with CRF may contribute to their uremic syndrome.

^* This work was supported by PHS Grants AM-19397,AM-25386, and 5M01-RR-349.

Received January 28, 1980.

This article has been cited by other articles:

				J. Lonovics, P. Devitt, L. C. Watson, P. L. Rayford, and J. C. Thompson Pancreatic Polypeptide: A Review Arch Surg, October 1, 1981; 116(10): 1256 - 1264. [Abstract] [PDF]